|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||324.467 g·mol−1|
|3D model (JSmol)|
JWH-176 is an analgesic drug which acts as a cannabinoid receptor agonist. Its binding affinity at the CB1 receptor is 26.0 nM, making it more potent than THC itself, however JWH-176 is particularly notable in that it is a hydrocarbon containing no heteroatoms. This demonstrates that reasonably high-affinity cannabinoid binding and agonist effects can be produced by compounds with no hydrogen bonding capacity at all, relying merely on Van der Waals interactions to bind to the receptor. It was discovered by, and named after, John W. Huffman.
JWH-176 is the (E)-stereoisomer of 1-([3-pentylinden-1-ylidine]methyl)naphthalene, whereas JWH-171 is the mixture of the (E)- and (Z)-isomers.
As of 23rd December 2009, any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by an alkyl group is a Class B drug in the United Kingdom. 
- Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Current Medicinal Chemistry, 2005; 12: 1395-1411.
- Roger Pertwee. Cannabinoids. Handbook of Experimental Pharmacology Volume 168, p 269. Springer. ISBN 3-540-22565-X
- Rahman, Atta-ur; Iqbal Choudhary, M; Reitz, Allen B (2010-12-10). Frontiers in Medicinal Chemistry , Volume (4). p. 681. ISBN 978-1608052073.
- : Schedules of controlled substances
- "The Misuse of Drugs Act 1971 (Amendment) Order 2009", legislation.gov.uk, The National Archives, SI 2009/3209